We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-10.62%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.76B
AUM Growth
-$25.9M
Cap. Flow
+$293M
Cap. Flow %
10.61%
Top 10 Hldgs %
58.38%
Holding
114
New
31
Increased
18
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
C icon
Citigroup
C
+$14.9M
2
DG icon
Dollar General
DG
+$14.5M
3
MJN
Mead Johnson Nutrition Company
MJN
+$12.2M
4
APTV icon
Aptiv
APTV
+$9.58M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.21M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$11.8M
2
GS icon
Goldman Sachs
GS
+$8.41M
3
CCI icon
Crown Castle
CCI
+$7.34M
4
XOMA
Xoma
XOMA
+$7.26M
5
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$5.55M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 22.6%
2 Healthcare 22.12%
3 Consumer Staples 1.28%
4 Financials 0.7%
5 Real Estate 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
51
CALL
Eli Lilly
LLY
$1.09T
$11.8M 0.43%
200,000
-400,000
-67% -$22.3M
APTV icon
52
Aptiv
APTV
$12.5B
$10.2M 0.37%
+150,000
New +$9.58M
EWW icon
53
CALL
iShares MSCI Mexico ETF
EWW
$1.9B
$9.59M 0.35%
+150,000
New +$9.4M
MU icon
54
CALL
Micron Technology
MU
$906B
$9.46M 0.34%
400,000
– –
PCYC
55
CALL
DELISTED
PHARMACYCLICS INC
PCYC
$9.02M 0.33%
90,000
+50,000
+125% +$6.5M
BRFS
56
DELISTED
BRF SA
BRFS
$8.93M 0.32%
+446,900
New +$8.18M
HAL icon
57
CALL
Halliburton
HAL
$26.4B
$8.83M 0.32%
+150,000
New +$8.01M
FURX
58
CALL
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$8.7M 0.31%
+100,000
New +$7.72M
ZTS icon
59
CALL
Zoetis
ZTS
$32.8B
$8.68M 0.31%
300,000
– –
MJN
60
CALL
DELISTED
Mead Johnson Nutrition Company
MJN
$8.31M 0.3%
100,000
-100,000
-50% -$8.11M
RL icon
61
CALL
Ralph Lauren
RL
$22.2B
$8.05M 0.29%
+50,000
New +$8.06M
RL icon
62
Ralph Lauren
RL
$22.2B
$8.05M 0.29%
+50,000
New +$8.06M
CERE
63
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$7.21M 0.26%
1,024,021
+500,000
+95% +$5.21M
FXI icon
64
CALL
iShares China Large-Cap ETF
FXI
$4.31B
$7.16M 0.26%
+200,000
New +$7M
FCX icon
65
CALL
Freeport-McMoran
FCX
$85.7B
$6.61M 0.24%
200,000
– –
HOUS
66
DELISTED
Anywhere Real Estate
HOUS
$6.52M 0.24%
150,000
-25,000
-14% -$1.17M
M icon
67
CALL
Macy's
M
$6.4B
$5.93M 0.21%
100,000
– –
INCY icon
68
Incyte
INCY
$25.6B
$5.35M 0.19%
+100,000
New +$6.21M
IMGN
69
CALL
DELISTED
Immunogen Inc
IMGN
$5.23M 0.19%
350,000
– –
XOMA
70
DELISTED
Xoma
XOMA
$5.21M 0.19%
50,000
-50,000
-50% -$7.26M
MTG icon
71
MGIC Investment
MTG
$6.51B
$5.11M 0.19%
600,000
+100,000
+20% +$870K
AVNR
72
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$4.77M 0.17%
1,300,000
+200,000
+18% +$762K
MRTX
73
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.77M 0.17%
250,000
+75,000
+43% +$1.56M
MS icon
74
CALL
Morgan Stanley
MS
$323B
$4.68M 0.17%
+150,000
New +$4.63M
NG icon
75
CALL
NovaGold Resources
NG
$2.51B
$4.33M 0.16%
1,200,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2014 Portfolio in Review

As of Q1 2014, Artal Group held 114 positions worth $2.76B, down 0.93% from $2.79B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group deployed $293M of net new capital in Q1 2014, opening 31 new positions and adding to 18 existing holdings. Its largest new stake was Citigroup: 300,000 shares worth $14.3M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 23% of assets, down from 35% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was Acorda Therapeutics, an estimated $11.8M trimmed.

  • Artal Group's largest Q1 2014 buy was Citigroup: 300,000 shares worth $14.3M.
  • Artal Group added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $9.21M increase.
  • Artal Group's biggest Q1 2014 reduction was Acorda Therapeutics, cutting an estimated $11.8M.
  • Artal Group fully exited Goldman Sachs in Q1 2014, selling an estimated $8.41M.
  • Artal Group's ten largest holdings make up 58% of its $2.76B portfolio in Q1 2014.
  • Artal Group opened 31 new positions and closed 20 in Q1 2014.
  • Artal Group's portfolio value fell 0.93% quarter-over-quarter to $2.76B.

Based on Artal Group's 13F filing for Q1 2014, filed 15 May 2014.